Get the Weekly Intelligence Brief — top committee picks every Sunday.
NTRA · NASDAQ · STOCK

Natera (NTRA) Stock Analysis

Healthcare Updated October 10, 2026
$400.47
52W $169.08 – $437.41
63/100
$57.39B
-294.6
1.50
AI Committee Verdict
Buy
63/100
Conviction: Contested · 67% agreement · 6 analysts
-37.9%
Contested

Is NTRA Bullish or Bearish?

Bullish. Innellis AI committee rates Natera, Inc. (NTRA) Buy with a composite score of 63/100 , based on 6 analysts with 67% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +11.96 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -8.04 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 37.8% yoy -- genuine top-line momentum. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Revenue growing 37.8% YoY -- genuine top-line momentum — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • Low leverage (debt-to-equity 0.05) -- balance sheet can absorb a shock — Risk
Bear Case
  • Price-to-book of 18.5x prices in significant intangible value — Value
  • ROE of only -11.7% -- cheap may mean cheap for a reason — Value
  • MACD histogram negative -- bearish momentum — Technical
  • Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
  • Bollinger bandwidth of 25.7% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
63/100
Agreement
67%
Analysts
6
Conviction
Contested
Sector Rank
Top 15%
of 192 Healthcare peers
Value Analyst neutral
43 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 18.5x prices in significant intangible value
Growth Analyst bullish
85 / 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 37.8% YoY -- genuine top-line momentum
Technical Analyst bullish
61 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst neutral
58 / 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.05) -- balance sheet can absorb a shock
− Bollinger bandwidth of 25.7% signals elevated volatility
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
66 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 26 articles, 14d)
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 62.2 to 63.0.

Analyst-level changes:
  • News Analyst: score 61->66 (+5); +1 bullish signal(s).
  • Risk Analyst: +1 bearish signal(s).
  • Technical Analyst: +1 bearish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
54.0
Neutral
MACD Histogram
-3.451
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.59
Inside Bands
Price vs Moving Averages
EMA 9
$400.77 Below
EMA 21
$387.02 Above
EMA 50
$351.46 Above
EMA 200
$270.42 Above

Fundamental Analysis

Valuation
67
Growth
85
Profitability
25
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio -294.6×
P/B Ratio 31.52×
PEG Ratio -18.15
Dividend Yield 0.00%
52W High $437.41
52W Low $169.08
Quality & Growth
ROE -1215.6%
ROA -830.0%
Gross Margin 6530.4%
Operating Margin -1070.0%
Revenue Growth YoY —
Debt / Equity 0.13
AI Fundamental Assessment
P/E ratio of -294.6 (inexpensive relative to a 15-40x range); Price-to-book of 31.5x; PEG ratio of -18.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -12.2%; Return on assets of -8.3%; Net margin of -7.1%; Gross margin of 65.3%; Current ratio of 3.00 (healthy short-term liquidity); Debt-to-equity of 0.13; Free cash flow per share is positive (0.50); Most recent quarter beat estimates by 6.7%; EPS growth accelerating (-266.7% -> +21.7% QoQ); Analyst estimates rising over recent quarters
Get the Full NTRA Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime